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each generic was used to estimate one month’s cost of hypertension treatment; 
considering the maximum and minimum dosage for each generic. The affordability 
of treatments was calculated by comparing the total cost of medicines to the daily 
official minimum wage ($63.12MXN, 2013 prices) Results: The number of days’ 
wages required to pay one month of antihypertensive therapy ranged from: 0.08-
4.18 for diuretics, 0.67-1.90 for beta blockers, 1.7-3.99 for calcium channel blockers, 
0.71-3.31 for ACE inhibitors and 2.38-8.11 for ARBs. ConClusions: Cost could be 
a substantial barrier for permanence in antihypertensive treatment, so that should 
be discussed measures to prevent this from happening.
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objeCtives: AF is the most common chronic cardiac arrhythmia worldwide. Most 
patients with AF need life-long treatment to be protected from ischemic stroke. The 
aim was to conduct a high level cost assessment for stroke prevention and manage-
ment in patients with AF [SPAF & SMAF] in 4 Latin American countries. Methods: 
Overall the costs of SPAF & SMAF were determined through 59 face-to-face interviews 
with cardiologists in Argentina, Brazil, Chile and Venezuela. Treatment costs were 
estimated using benchmarks from major private and public hospitals in each coun-
try. Results: On average, the largest component of real-life medical expenditures 
for SPAF, under appropriate treatment given CHADS2 scores, was prescription drugs, 
which ranged from 68% in private to 75% in public. Annual SPAF treatment ranged in 
price from US$425 in Argentina to US$1,935 in Chile in private institutions and US$85 
in Brazil to US$1,199 in Venezuela in public institutions. Moreover, overall treatment 
costs in Chile were 5X higher than the least expensive country in each sector. For 
SMAF, using rivaroxaban vs the common Vitamin K antagonists resulted in a 24%-46% 
cost reduction for disease treatment at a national level due to better patient adher-
ence. This would decrease the stroke incidence/year, which would translate to US$143 
M /yr in savings. ConClusions: AF is an important source of health care resource 
utilization because of repeated medical examinations, extensive use of laboratory 
tests and pharmacological treatments. Private and public institution cost differences 
are common in all 4 countries. Improving access to novel drugs, such as rivaroxaban, 
could help improve cost allocation, inducing a savings opportunity in each country.
PCV21
healTh-eConomIC assessmenT of The use of CaTheTer-based renal 
denerVaTIon In PaTIenTs wITh resIsTanT hyPerTensIon In mexICo
Ceballos R.M.1, Sanchez-Kiobashi R.2, Gay J.G.3, Pietzsch J.B.4, Geisler B.P.4
1Medtronic, Mexico DF, Mexico, 2TI Salud, Mexico DF, Mexico, 3T.I. Salud, Mexico, México D.F., 
Mexico, 4Wing Tech Inc., Menlo Park, CA, USA
objeCtives: Catheter-based renal denervation (RDN) is a new therapy for resistant 
hypertension, a condition that affects approx. 10-15% of hypertensive patients, in 
which blood pressure is uncontrolled despite the simultaneous use of three or more 
antihypertensive drugs. Our objective was to assess clinical and cost-effectiveness 
of RDN compared to standard of care (SoC) from the Mexican public payer per-
spective. Methods: A previously published lifetime Markov model was adapted 
to the Mexican setting to predict clinical endpoints (death, myocardial infarction, 
stroke, heart failure, coronary heart disease, end-stage renal disease) and costs - 
based on Mexican epidemiological and cost data. We evaluated the impact of a 
32 mmHg reduction in systolic blood pressure, from a baseline of 178 mmHg, in 
a 58-year old 43% female, 34% diabetic, and 16% smoking cohort, as observed in 
the Symplicity HTN-2 randomized controlled trial. Direct public health care costs 
were estimated from the published literature and from governmental databases. 
The incremental cost-effectiveness ratio (ICER) was computed as incremental costs 
per life-year gained, discounted at 3%. Deterministic sensitivity analyses were 
performed. Results: RDN was projected to reduce cardiovascular endpoints by 
22-32% over 10 yrs., and 7-17% over lifetime. The lifetime ICER was estimated at 
MXN$ 194,128 (US$ 14,750) per LY gained, and had an incremental cost of MXN$ 
117,916 (US$ 8,959) compared to SoC. Application of higher discount rates led to 
a measured increase in the ICER. ConClusions: Our model projections suggest 
that RDN reduces and delays cardiovascular events and is a cost-effective therapy 
in Mexico when considering most international willingness-to-pay thresholds, but 
remains above the current national government threshold of one GDP/capita of 
MXN$ 139,900 (US$ 10,630) per additional life year.
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objeCtives: Aortic stenosis is the most common valvular heart disease in the elderly 
– its prevalence is estimated to be up to 5% in individuals over 75 years. Surgical 
replacement of the aortic valve is considered the standard care and in the absence 
of serious coexisting conditions, the procedure is associated with low operative mor-
tality. However, a significant proportion of patients can not undergo surgery due to 
a high surgical risk associated with advanced age or with the presence of multi-
ple coexisting conditions. Treatment with transcatheter aortic-valve implantation 
(TAVI) is a therapy with potentially lower peri-procedure risk and has been used as 
a therapeutic option in this group of patients considered inoperable. Therefore, this 
study aims to develop a cost-effectiveness analysis of TAVI in patients with severe 
aortic stenosis who are not suitable for surgical treatment. Methods: A Markov 
model was developed to compare the TAVI versus standard therapy (drug treatment 
2011. One-year costs were identified by applying cost data to medical informa-
tion obtained by review of medical records. Costs included those for medications, 
laboratory and diagnostic tests, clinic visits, emergency room visits and hospital 
stays. Contemporary data were obtained from epidemiological studies, government 
datasets, and other sources to estimate prevalence. National costs (US dollar 2012) 
of treatment for PAH were estimated by extrapolation of mean cost estimate per 
person to national incidence data for PAH. Because of uncertainties surrounding 
some of our estimates such as prevalence, one way sensitivity analyses were under-
taken. Results: A total of 113 PAH patients were identified and their demographic 
and clinical characteristics, patterns of care were examined. The mean age was 38 
years, and 83% were female. The average per patient annual cost was $ 10,869 with-
out specific treatment (min $ 137; max $155,928). The annual cost for the treatment 
of a single PAH patient per year with specific therapy (Bosentan) was calculated in 
$31.433. Aggregate national health care expenditures for treatment of PAH were 
USD 46.6 million In multivariate analysis, length of hospital stay, stay in ICU, were 
all significant independent predictors of treatment. ConClusions: There is a cor-
relation between the cost of HAP and disease severity with hospitalization owing 
to disease severity being a major contributor to cost. With the expected increase in 
the incidence of PAH in Mexico over the coming decades, these results emphasize 
the need for effective preventive and acute medical care.
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objeCtives: To estimate the procedure (implantation) cost, the total hospitalization 
cost and annual follow-up cost, in patients subjected to pacemaker (PM) and implant-
able cardioverter-defibrillator (ICD) implantation. Methods: A single-center, pro-
spective, cost-of-illness study was conducted between August 2008 and July 2009. In 
total, 464 consecutive patients were recruited (370 were subjected to PM implantation 
and 94 to ICD implantation). Resource data were assessed at patients’ enrolment in 
the study and at 6th and 12th months of patients’ follow-up. Then, the procedure cost, 
the total hospitalization cost as well as the annual patients’ follow up costs were cal-
culated using a bottom-up approach. Results: The mean (95% confidence interval) 
procedure cost of PM and ICD implantation (including the costs of devices, electrodes, 
other supplies, and personnel’s time) was calculated to be € 1803 (€ 1758–€ 1858) and 
€ 13 521 (€ 13 153–€ 13 892), respectively. The mean total hospitalization cost (includ-
ing procedure cost, hospitalization cost, cost of laboratory and imaging diagnostic 
examinations and the indirect cost attributed to productivity lost due to patient’s 
hospitalization) was € 3926 (€ 3711–€ 4167) for PM and € 17 764 (€ 16 852–€ 18 692) for ICD. 
The mean annual cost (direct and indirect) was € 1816 (€ 1433–€ 2421) for PM and € 2819 
(€ 2115–€ 3703) for ICD. No difference was detected in the annual cost between patients 
with initial implantation and replacement. ConClusions: These data revealed that 
although these devices are associated with a relatively high upfront cost, the annual 
societal cost following the implantation is low. Therefore, implantation of such devices 
should be encouraged since these devices reduce the morbidity and mortality without 
a high economic burden to society.
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objeCtives: To calculate cost of illness due to coronary heart disease in the patients 
attending National Heart Center, Kathmandu, Nepal. Methods: Descriptive cross 
sectional survey was conducted. The total number of sample was 120. The sam-
ple was selected by non-probability purposive sampling method. Data entry and 
analysis was done using SPSS 16.0. Categorical variables were compared using 
Independent Sample t-test and cross tabulation was done and chi- square test was 
applied to show significant difference between variables. Results: Agriculture was 
the main source of income of the coronary heart disease household and the aver-
age annual household income was NRs. 1, 54,000 (US $ 1792). The study estimated 
the average cost of illness to be NRs. 30,888.14 (US $ 360) for an outpatient episode 
of coronary heart disease which was 20.05% of the average annual income of CHD 
household. The average total time loss of the CHD household was 8.75 person days. 
The average total direct cost was NRs. 29,600 (US $ 344) of which medical cost was 
the largest component. The average monetary value of time loss by the household 
was found to be 2,981.18 (US $ 35). ConClusions: The study found high cost of 
illness due to centralised system of health care.The findings of the study showed 
that households struggled to cope and adopted unsustainable strategies that dam-
aged asset and caused or sustained impoverishment. Thus, estimated cost appears 
to be sustained economic burden on the individual household.
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objeCtives: Hypertension (HT) is one of the most prevalent chronic diseases in 
Mexico. In the last two decades, a substantial increase in the prevalence of HT was 
observed in Mexico from 25% in 1993 to 43.2% in 2006 in adult population (≥ 20 
years old). Almost 50% of population is not under a social security scheme and 
many patients pay for medicines out-of-pocket. This study’s aim was to calculate 
the affordability of different kinds of antihypertensive drugs in Mexico. Methods: 
Price data for 5 classes of antihypertensive drugs (diuretics, beta blockers, calcium 
channel blockers, ACE inhibitors and angiotensin II receptor antagonists or ARBs) 
were obtained from public internet sources, and the lowest price identified for 
